サイコサポニンA (Synonyms: Saikosaponin A)

Name: Saikosaponin A
Brand: MedChemExpress
SKU: HY-N0246
Rating: 5.0 (5 reviews)

製品番号: HY-N0246 純度: 99.31%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

Saikosaponin A is the main active ingredient in Bupleurum chinense, which can regulate lipid metabolism and promote cholesterol efflux in early atherosclerosis. In addition, Saikosaponin A may also serve as a potential peroxisome proliferator-activated receptor γ (PPAR-γ) agonist, significantly promoting the expression of PPAR-γ. Saikosaponin A can be used in the study of hyperlipidemic pancreatitis.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 20736-09-8

容量	価格（税別）	在庫状況	数量
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 60	在庫あり	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 60	在庫あり	Estimated Time of Arrival: December 31
Solid
5 mg	$35	在庫あり	Estimated Time of Arrival: December 31
10 mg	$60	在庫あり	Estimated Time of Arrival: December 31
25 mg	$125	在庫あり	Estimated Time of Arrival: December 31
50 mg	$210	在庫あり	Estimated Time of Arrival: December 31
100 mg	$360	在庫あり	Estimated Time of Arrival: December 31
200 mg		お問い合わせ
500 mg		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 5 publication(s) in Google Scholar

Other Forms of Saikosaponin A:

Saikosaponin A (Standard) お問い合わせ

顧客検証

RT-PCR

Histological Imaging/Staining

: Saikosaponin A purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2023 Sep;28(3):159. [Abstract]; Cardiomyocytes were pretreated with Saikosaponin A (SSA) (1, 10 and 30 µmol/L) for 1 h then exposed to IAA (50 µmol/L) for 48 h and mRNA expression levels of ANP, BNP and β-MHC were analyzed by qPCR.

: Saikosaponin A purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2023 Sep;28(3):159. [Abstract]; Cardiomyocytes were pretreated with Saikosaponin A (SSA) (30 µmol/L) for 1 h and then exposed to IAA (50 µmol/L) for 48 h and Trim16 protein expression measured by Western blotting.

: Saikosaponin A purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2023 Sep;28(3):159. [Abstract]; Representative micrographs (magnification, 10×) of hematoxylin and eosin-stained transverse sections from hearts of control, IAA- and IAA + Saikosaponin A (SSA) (40 mg/kg, i.g.)-treated mice.

: Saikosaponin A purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2023 Sep;28(3):159. [Abstract]; Cardiomyocytes were transfected with siTrim16 or scrambled siRNA (siCntl), treated with Saikosaponin A (SSA) (30 µmol/L) for 1 h, then incubated with IAA (50 µmol/L) for 48 h. K48 ubiquitination of RIP2 was measured by immunoprecipitation.

: Saikosaponin A purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2023 Sep;28(3):159. [Abstract]; Cell size was observed by immunofluorescence using a troponin antibody treated with Saikosaponin A (SSA) (30 µmol/L).

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

生物活性
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	23.9 3 Compound: 1	Cytotoxicity against human A375 cells after 48 hrs by SRB assay Cytotoxicity against human A375 cells after 48 hrs by SRB assay	[PMID: 19467877]
A-375	IC₅₀	23.9 3 Compound: 1	Cytotoxicity against human A375 cells after 48 hrs by SRB assay Cytotoxicity against human A375 cells after 48 hrs by SRB assay	[PMID: 19467877]
A549	IC₅₀	17.7 3 Compound: 1	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 19467877]
A549	IC₅₀	14.54 3 Compound: 8	Cytotoxicity against human A549 cells assessed as induction of cell death incubated for 2 days by MTT assay Cytotoxicity against human A549 cells assessed as induction of cell death incubated for 2 days by MTT assay	[PMID: 26259802]
A549	IC₅₀	14.54 3 Compound: 8	Cytotoxicity against human A549 cells assessed as induction of cell death incubated for 2 days by MTT assay Cytotoxicity against human A549 cells assessed as induction of cell death incubated for 2 days by MTT assay	[PMID: 26259802]
A549	IC₅₀	17.7 3 Compound: 1	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 19467877]
ACHN	IC₅₀	> 50 3 Compound: 1	Cytotoxicity against human ACHN cells after 48 hrs by SRB assay Cytotoxicity against human ACHN cells after 48 hrs by SRB assay	[PMID: 19467877]
ACHN	IC₅₀	>50 3 Compound: 1	Cytotoxicity against human ACHN cells after 48 hrs by SRB assay Cytotoxicity against human ACHN cells after 48 hrs by SRB assay	[PMID: 19467877]
Bcap37	IC₅₀	13.96 3 Compound: 8	Cytotoxicity against human Bcap37 cells assessed as induction of cell death incubated for 2 days by MTT assay Cytotoxicity against human Bcap37 cells assessed as induction of cell death incubated for 2 days by MTT assay	[PMID: 26259802]
Bcap37	IC₅₀	13.96 3 Compound: 8	Cytotoxicity against human Bcap37 cells assessed as induction of cell death incubated for 2 days by MTT assay Cytotoxicity against human Bcap37 cells assessed as induction of cell death incubated for 2 days by MTT assay	[PMID: 26259802]
C32	IC₅₀	43.5 3 Compound: 1	Cytotoxicity against human C32 cells after 48 hrs by SRB assay Cytotoxicity against human C32 cells after 48 hrs by SRB assay	[PMID: 19467877]
C32	IC₅₀	43.5 3 Compound: 1	Cytotoxicity against human C32 cells after 48 hrs by SRB assay Cytotoxicity against human C32 cells after 48 hrs by SRB assay	[PMID: 19467877]
COR-L23	IC₅₀	0.6 3 Compound: 1	Cytotoxicity against human COR-L23 cells after 48 hrs by SRB assay Cytotoxicity against human COR-L23 cells after 48 hrs by SRB assay	[PMID: 19467877]
Caco-2	IC₅₀	17.9 3 Compound: 1	Cytotoxicity against human Caco-2 cells after 48 hrs by SRB assay Cytotoxicity against human Caco-2 cells after 48 hrs by SRB assay	[PMID: 19467877]
Caco-2	IC₅₀	17.9 3 Compound: 1	Cytotoxicity against human Caco-2 cells after 48 hrs by SRB assay Cytotoxicity against human Caco-2 cells after 48 hrs by SRB assay	[PMID: 19467877]
COR-L23	IC₅₀	0.6 3 Compound: 1	Cytotoxicity against human COR-L23 cells after 48 hrs by SRB assay Cytotoxicity against human COR-L23 cells after 48 hrs by SRB assay	[PMID: 19467877]
Hep 3B2	IC₅₀	13.01 3 Compound: 8	Cytotoxicity against human Hep3B cells assessed as induction of cell death incubated for 2 days by MTT assay Cytotoxicity against human Hep3B cells assessed as induction of cell death incubated for 2 days by MTT assay	[PMID: 26259802]
Hep 3B2	IC₅₀	13.01 3 Compound: 8	Cytotoxicity against human Hep3B cells assessed as induction of cell death incubated for 2 days by MTT assay Cytotoxicity against human Hep3B cells assessed as induction of cell death incubated for 2 days by MTT assay	[PMID: 26259802]
HepG2	IC₅₀	8.34 3 Compound: 8	Cytotoxicity against human HepG2 cells assessed as induction of cell death incubated for 2 days by MTT assay Cytotoxicity against human HepG2 cells assessed as induction of cell death incubated for 2 days by MTT assay	[PMID: 26259802]
HepG2	IC₅₀	8.34 3 Compound: 8	Cytotoxicity against human HepG2 cells assessed as induction of cell death incubated for 2 days by MTT assay Cytotoxicity against human HepG2 cells assessed as induction of cell death incubated for 2 days by MTT assay	[PMID: 26259802]
LNCaP	IC₅₀	>50 3 Compound: 1	Cytotoxicity against human LNCAP cells after 48 hrs by SRB assay Cytotoxicity against human LNCAP cells after 48 hrs by SRB assay	[PMID: 19467877]
LNCaP	IC₅₀	> 50 3 Compound: 1	Cytotoxicity against human LNCAP cells after 48 hrs by SRB assay Cytotoxicity against human LNCAP cells after 48 hrs by SRB assay	[PMID: 19467877]
MCF7	IC₅₀	>50 3 Compound: 1	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 19467877]
MCF7	IC₅₀	18.99 3 Compound: 8	Cytotoxicity against human MCF7 cells assessed as induction of cell death incubated for 2 days by MTT assay Cytotoxicity against human MCF7 cells assessed as induction of cell death incubated for 2 days by MTT assay	[PMID: 26259802]
MCF7	IC₅₀	18.99 3 Compound: 8	Cytotoxicity against human MCF7 cells assessed as induction of cell death incubated for 2 days by MTT assay Cytotoxicity against human MCF7 cells assessed as induction of cell death incubated for 2 days by MTT assay	[PMID: 26259802]
MCF7	IC₅₀	> 50 3 Compound: 1	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 19467877]
RAW264.7	IC₅₀	101.8 3 Compound: 1	Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production after 24 hrs by Griess reagent method Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production after 24 hrs by Griess reagent method	[PMID: 19467877]
RAW264.7	IC₅₀	101.8 3 Compound: 1	Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production after 24 hrs by Griess reagent method Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production after 24 hrs by Griess reagent method	[PMID: 19467877]
RAW264.7	IC₅₀	>200 3 Compound: 1	Cytotoxicity against mouse RAW264.7 cells by MTT assay Cytotoxicity against mouse RAW264.7 cells by MTT assay	[PMID: 19467877]
RAW264.7	IC₅₀	> 200 3 Compound: 1	Cytotoxicity against mouse RAW264.7 cells by MTT assay Cytotoxicity against mouse RAW264.7 cells by MTT assay	[PMID: 19467877]

体外実験

Saikosaponin A (5-15 μM, 24 h) did not affect the viability of human osteoarthritis chondrocytes^[1].
Saikosaponin A (5-15 μM, 24 h) inhibits IL-1β (HY-P73149)-induced NO and PGE2 production and NF-κB activation^[1].
Saikosaponin A (5-15 μM, 24 h) up-regulates the expression of LXRα in a dose-dependent manner^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	Human osteoarthritis chondrocytes
Concentration:	5, 10, 15 μM
Incubation Time:	24 h
Result:	Inhibited the levels of phosphorylation of NF-κB p65 and IκBα induced by IL-1β. Up-regulated the expression of LXRα in a dose-dependent manner.

体内実験

Saikosaponin A (1-10 mg/kg, i.p, 7 d) attenuates the morphological changes in the small intestine induced by 5-FU^[2].
Saikosaponin-A (1-10 mg/kg, i.p, 7 d) enhances the decrease of antioxidant enzymes in intestinal tissue caused by 5-FU^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	5-FU (HY-90006)-induced mucositis in BALB/c mice modle^[2]
Dosage:	1, 5, 10 mg/kg/day, 7 d
Administration:	injected intraperitoneally (i.p)
Result:	Reduced villus blunting, crypt cells apoptosis, and inflammatory cell infiltration. Decreased concentration of GSH, GST, Catalase, and SOD in intestinal tissue.

分子量

780.98

分子式

C₄₂H₆₈O₁₃

CAS 番号

20736-09-8

Appearance

Solid

Color

White to off-white

SMILES

OC[C@H]1O[C@](O[C@@H]2[C@@H](O)[C@@](O[C@@H]3[C@@](C)(CO)[C@@](CC[C@]4(C)[C@]5([H])C=C[C@@]6(OC7)[C@@]4(C)C[C@H](O)[C@]87[C@@]6([H])CC(C)(C)CC8)([H])[C@]5(C)CC3)([H])O[C@H](C)[C@@H]2O)([H])[C@H](O)[C@@H](O)[C@@H]1O

Structure Classification

Initial Source

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

-20°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (128.04 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.2804 mL	6.4022 mL	12.8044 mL
5 mM	0.2561 mL	1.2804 mL	2.5609 mL
10 mM	0.1280 mL	0.6402 mL	1.2804 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）

体積 _（開始）

濃度 _（終了）

体積 _（終了）

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.20 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (3.20 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (3.20 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 10 mg/mL (12.80 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

純度とドキュメンテーション

純度: 99.31%

Select Batch:

データシート (282 KB) SDS (394 KB)

COA (253 KB) LCMS (100 KB)

取扱説明書 (2659 KB)

参考文献

[1]. Gao H, et al. Saikosaponin A inhibits IL-1β-induced inflammatory mediators in human osteoarthritis chondrocytes by activating LXRα. Oncotarget. 2017 Sep 30;8(51):88941-88950. [Content Brief]

[2]. Jawad Ali, et al. Mucoprotective effects of Saikosaponin-A in 5-fluorouracil-induced intestinal mucositis in mice model. Life Sci. 2019. [Content Brief]

[3]. Feng P, et al. Saikosaponin a attenuates hyperlipidemic pancreatitis in rats via the PPAR‑γ/NF‑κB signaling pathway[J]. Experimental and therapeutic medicine, 2020, 19(2): 1203-1212. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.2804 mL	6.4022 mL	12.8044 mL	32.0111 mL
	5 mM	0.2561 mL	1.2804 mL	2.5609 mL	6.4022 mL
	10 mM	0.1280 mL	0.6402 mL	1.2804 mL	3.2011 mL
	15 mM	0.0854 mL	0.4268 mL	0.8536 mL	2.1341 mL
	20 mM	0.0640 mL	0.3201 mL	0.6402 mL	1.6006 mL
	25 mM	0.0512 mL	0.2561 mL	0.5122 mL	1.2804 mL
	30 mM	0.0427 mL	0.2134 mL	0.4268 mL	1.0670 mL
	40 mM	0.0320 mL	0.1601 mL	0.3201 mL	0.8003 mL
	50 mM	0.0256 mL	0.1280 mL	0.2561 mL	0.6402 mL
	60 mM	0.0213 mL	0.1067 mL	0.2134 mL	0.5335 mL
	80 mM	0.0160 mL	0.0800 mL	0.1601 mL	0.4001 mL
	100 mM	0.0128 mL	0.0640 mL	0.1280 mL	0.3201 mL

Saikosaponin A Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量		濃度		体積		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）	×	体積 _（開始）	=	濃度 _（終了）	×	体積 _（終了）
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Saikosaponin A20736-09-8LXRBacterialLiver X receptorInhibitorinhibitorinhibit

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
製品名			カスタマ需要量 *
お名前 *			タイトル
メールアドレス *			電話番号 *
デパートメント			組纖名 *
市区町村			都道府県
国或いは地域 *
必ず会社名を記載ください。個人への返信は行いません。
備考

製品名			Lot #
お名前 *			メールアドレス *
電話番号 *			部門 *
組纖名 *			国或いは地域 *
備考

お名前
メール *

	Sorry, but the email address you supplied was invalid.

サイコサポニンA (Synonyms: Saikosaponin A)

カスタマーレビュー

Other Forms of Saikosaponin A:

サイコサポニンA 関連抗体

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

サイコサポニンA 関連抗体

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Saikosaponin A Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

カスタマーレビュー

Request for HNMR Report

Request for HNMR Report